Robecosam AG reduced its position in Zoetis Inc (NYSE:ZTS) by 4.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,292 shares of the company’s stock after selling 1,012 shares during the quarter. Robecosam AG’s holdings in Zoetis were worth $2,288,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Cibc Bank USA boosted its stake in shares of Zoetis by 18.1% in the 2nd quarter. Cibc Bank USA now owns 3,538 shares of the company’s stock valued at $402,000 after buying an additional 543 shares during the period. Wrapmanager Inc. boosted its stake in shares of Zoetis by 8.8% in the 2nd quarter. Wrapmanager Inc. now owns 11,451 shares of the company’s stock valued at $1,300,000 after buying an additional 922 shares during the period. CWM LLC boosted its stake in shares of Zoetis by 88.8% in the 2nd quarter. CWM LLC now owns 1,535 shares of the company’s stock valued at $174,000 after buying an additional 722 shares during the period. Geneva Partners LLC boosted its stake in shares of Zoetis by 9.8% in the 2nd quarter. Geneva Partners LLC now owns 36,665 shares of the company’s stock valued at $4,161,000 after buying an additional 3,275 shares during the period. Finally, Signaturefd LLC boosted its stake in shares of Zoetis by 14.2% in the 2nd quarter. Signaturefd LLC now owns 2,953 shares of the company’s stock valued at $335,000 after buying an additional 368 shares during the period. 90.08% of the stock is owned by institutional investors.
ZTS stock traded down $2.33 during trading on Wednesday, hitting $122.37. 32,236 shares of the company’s stock were exchanged, compared to its average volume of 2,156,563. The firm’s 50-day moving average price is $115.93. The firm has a market capitalization of $59.87 billion, a PE ratio of 39.41, a price-to-earnings-growth ratio of 3.16 and a beta of 0.92. Zoetis Inc has a 52-week low of $78.90 and a 52-week high of $125.88. The company has a debt-to-equity ratio of 2.74, a current ratio of 4.17 and a quick ratio of 2.87.
Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 6th. The company reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.82 by $0.08. The firm had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.51 billion. Zoetis had a return on equity of 72.86% and a net margin of 22.74%. The firm’s revenue was up 9.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.77 earnings per share. On average, equities research analysts predict that Zoetis Inc will post 3.57 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 19th will be paid a $0.164 dividend. This represents a $0.66 dividend on an annualized basis and a yield of 0.54%. The ex-dividend date is Thursday, July 18th. Zoetis’s dividend payout ratio is currently 21.09%.
In other Zoetis news, Director Willie M. Reed sold 1,900 shares of the business’s stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $110.58, for a total value of $210,102.00. Following the completion of the sale, the director now owns 2,816 shares in the company, valued at $311,393.28. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Heidi C. Chen sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $104.23, for a total value of $260,575.00. Following the completion of the sale, the insider now owns 11,463 shares of the company’s stock, valued at approximately $1,194,788.49. The disclosure for this sale can be found here. In the last quarter, insiders sold 29,537 shares of company stock valued at $3,184,955. 0.29% of the stock is owned by company insiders.
Several equities analysts have recently issued reports on the company. SunTrust Banks lifted their price objective on Zoetis from $120.00 to $130.00 and gave the company a “hold” rating in a research note on Tuesday. Gabelli cut Zoetis from a “buy” rating to a “hold” rating and set a $108.00 price objective for the company. in a research note on Thursday, May 2nd. They noted that the move was a valuation call. BMO Capital Markets lifted their price objective on Zoetis from $101.00 to $105.00 and gave the company a “market perform” rating in a research note on Thursday, May 9th. Zacks Investment Research cut Zoetis from a “buy” rating to a “hold” rating in a research note on Monday, May 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $130.00 price objective (up previously from $116.00) on shares of Zoetis in a research note on Wednesday, June 12th. Seven research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Zoetis has an average rating of “Buy” and an average price target of $115.13.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Recommended Story: What is a blue-chip stock?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.